

### ICD-10 MS-DRGs Version 38.1 Effective January 01, 2021

In response to the COVID-19 pandemic, the Centers for Medicare & Medicaid Services (CMS) is implementing 21 new procedure codes to describe the introduction or infusion of therapeutics, including monoclonal antibodies and vaccines for COVID-19 treatment, into the International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), effective January 01, 2021.

CMS notes that for hospitalized patients, Medicare pays for the COVID-19 vaccines and their administration separately from the Diagnosis-Related Group rate. As such Medicare expects that the appropriate [CPT codes](#) will be used when a Medicare beneficiary is administered a vaccine while a hospital inpatient. For details on billing Medicare for the COVID-19 vaccine appropriately, please see this page in our provider toolkit:

<https://www.cms.gov/medicare/covid-19/medicare-billing-covid-19-vaccine-shot-administration>.

The ICD-10 MS-DRG Grouper assigns each case into an MS-DRG based on the reported diagnosis and procedure codes and demographic information (age, sex, and discharge status).

The ICD-10 Medicare Code Editor (MCE) Version 38.1 software uses edits to detect and report errors in the claims data for the ICD-10 codes reported to validate correct coding on claims for discharges on or after January 1, 2021.

The ICD-10 MS-DRG Grouper software package to accommodate these new codes, Version 38.1, is effective for discharges on or after January 1, 2021. As indicated in the table below, these codes will not affect the MS-DRG assignment.

Procedure Code	Description	*O.R.	MDC	MS-DRG
XW013H6	Introduction of other new technology monoclonal antibody into subcutaneous tissue, percutaneous approach, new technology group 6	N		
XW013K6	Introduction of leronlimab monoclonal antibody into subcutaneous tissue, percutaneous approach, new technology group 6	N		
XW013S6	Introduction of COVID-19 vaccine dose 1 into subcutaneous tissue, percutaneous approach, new technology group 6	N		
XW013T6	Introduction of COVID-19 vaccine dose 2 into subcutaneous tissue, percutaneous approach, new technology group 6	N		
XW013U6	Introduction of COVID-19 vaccine into subcutaneous tissue, percutaneous approach, new technology group 6	N		
XW023S6	Introduction of COVID-19 vaccine dose 1 into muscle, percutaneous approach, new technology group 6	N		
XW023T6	Introduction of COVID-19 vaccine dose 2 into muscle, percutaneous approach, new technology group 6	N		

XW023U6	Introduction of COVID-19 vaccine into muscle, percutaneous approach, new technology group 6	N		
XW033E6	Introduction of etesevimab monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6	N		
XW033F6	Introduction of bamlanivimab monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6	N		
XW033G6	Introduction of REGN-COV2 monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6	N		
XW033H6	Introduction of other new technology monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6	N		
XW033L6	Introduction of CD24Fc immunomodulator into peripheral vein, percutaneous approach, new technology group 6	N		
XW043E6	Introduction of etesevimab monoclonal antibody into central vein, percutaneous approach, new technology group 6	N		
XW043F6	Introduction of bamlanivimab monoclonal antibody into central vein, percutaneous approach, new technology group 6	N		
XW043G6	Introduction of REGN-COV2 monoclonal antibody into central vein, percutaneous approach, new technology group 6	N		
XW043H6	Introduction of other new technology monoclonal antibody into central vein, percutaneous approach, new technology group 6	N		
XW043L6	Introduction of CD24Fc immunomodulator into central vein, percutaneous approach, new technology group 6	N		
XW0DXM6	Introduction of baricitinib into mouth and pharynx, external approach, new technology group 6	N		
XW0G7M6	Introduction of baricitinib into upper GI, via natural or artificial opening, new technology group 6	N		
XW0H7M6	Introduction of baricitinib into lower GI, via natural or artificial opening, new technology group 6	N		

\*As the procedure codes are designated as non-O.R. procedures, there is no assigned MDC or MS-DRG. The ICD-10 MS-DRG assignment is dependent on the reported principal diagnosis, any secondary diagnoses defined as a complication or comorbidity (CC) or major complication or comorbidity (MCC), procedures or services performed, age, sex, and discharge status.

The ICD-10 MS-DRG V38.1 Grouper Software, Definitions Manual Table of Contents and the Definitions of Medicare Code Edits V38.1 manual will be available at <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software.html>

The Code Tables, Index and related Addenda files for the 21 new procedure codes are available at: <https://www.cms.gov/medicare/icd-10/2021-icd-10-pcs>